Position · Speculative Sleeve
Tempus AI, Inc. (TEM)
Compare vs. competitors: Tempus AI vs. Veeva Systems →
Read the full Q1 2026 earnings report →
Subscribe to TEM updates (RSS) →
Download full 3-statement model (.xlsx) →
Thesis StatementTempus AI's data-licensing segment is growing faster than its core diagnostics business, positioning it to capture more of the AI-in-healthcare opportunity as biopharma demand accelerates.
Core Thesis
Tempus AI builds the Tempus Platform, combining clinical, molecular, and imaging data using generative AI to inform treatment decisions, aiming to win adoption among health systems and pharma partners — applying AI directly to healthcare data and diagnostics...
Financial Metrics
- Market Cap$10.82B
- P/E (TTM)N/A — pre-profit; trailing EPS is negative
- EPS (TTM)-$1.72
- Div. Yield0.00%
- Price$60.27
Bear Case
Reimbursement or regulatory hurdles slow adoption of AI-driven diagnostics, competition from larger, better-capitalized healthcare-data players intensifies, and the company needs to raise additional capital before reaching profitability, diluting existing...
Investment Thesis
- The Thesis
- Tempus AI builds the Tempus Platform, combining clinical, molecular, and imaging data using generative AI to inform treatment decisions, aiming to win adoption among health systems and pharma partners — applying AI directly to healthcare data and diagnostics rather than to infrastructure or chips.
- The Catalyst
- Continued adoption of its "Intelligent Diagnostics" offering among health systems and pharma partners is the concrete growth driver to watch, as the company works toward profitability on a still-small, speculative-sleeve position.
- The Risk
- Reimbursement or regulatory hurdles could slow adoption of AI-driven diagnostics, and if the company needs to raise additional capital before reaching profitability, existing shareholders would be diluted.
- The Connection
- An AI-driven healthcare bet — a genuinely different vertical application of AI than the infrastructure, compute, and chip names that dominate the rest of my book, even though it shares the same underlying technology wave.
Pre-Mortem Thesis Invalidation Parameters
Codified in advance, before any of these have happened, so a future decision to hold or exit isn't rationalized in the moment. If a condition below is met, the thesis as written is invalidated and the position gets re-underwritten from scratch — not automatically sold, but automatically questioned.
| Metric / Event | Automatic Review Trigger |
|---|---|
| Reimbursement / Regulatory Pathway | A material reimbursement decision goes against AI-driven diagnostics adoption. |
| Capital Raise Dilution | The company raises additional equity capital before reaching its own guided profitability timeline. |
| Market cap | $10.82B |
|---|---|
| P/E ratio (TTM) | N/A — pre-profit; trailing EPS is negative |
| EPS (TTM) | -$1.72 |
| Dividend yield | 0.00% |
| Shares outstanding | N/A — not provided |
| Sector | Services-Computer Programming/Data Processing |
| EBITDAEarnings Before Interest, Taxes, Depreciation, and Amortization — a measure of operating profitability before financing and accounting decisions. EV/EBITDA compares a company's full value (including debt) to this figure, often used to compare companies with different capital structures. | FY26 guidance ~$65M adj. EBITDA on $1.59–1.60B revenue |
| PEG ratioPrice/Earnings-to-Growth: the P/E ratio divided by expected earnings growth. Below 1.0 is often read as cheap relative to growth; above suggests the market is pricing in a lot of future growth already. Different providers use different growth-rate assumptions, so figures vary by source. | Not disclosed in public data as of this writing |
| Capex | −$21.05M (TTM) |
Valuation Logic
Trailing EPS is negative, so there is no P/E to anchor on; the valuation case depends on the faster-growing Data & Applications segment reaching a scale where it can offset diagnostics-segment costs and turn the business toward profitability.
About the business
Tempus AI builds the Tempus Platform, an AI-driven precision-medicine and healthcare-data platform. Its "Intelligent Diagnostics" offering uses generative AI to deliver more accurate, personalized lab tests, aiming to combine clinical, molecular, and imaging data to inform treatment decisions.
Why it's in the speculative sleeve
Tempus is a pre-profit growth company applying AI directly to healthcare data and diagnostics — a genuinely different application of the AI theme than the infrastructure and chip names that dominate the rest of my book. It's sized small and treated as speculative because it's unprofitable, healthcare data/AI regulatory and reimbursement dynamics are hard for me to underwrite with confidence, and the stock is well off its 52-week high.
Risk/Reward Profile
| Bull Case | Bear Case |
|---|---|
| Intelligent Diagnostics and the broader Tempus Platform keep winning adoption among health systems and pharma partners, the company reaches sustained profitability as its data and testing volumes scale, and AI-driven precision medicine becomes a larger, more accepted part of standard care. | Reimbursement or regulatory hurdles slow adoption of AI-driven diagnostics, competition from larger, better-capitalized healthcare-data players intensifies, and the company needs to raise additional capital before reaching profitability, diluting existing shareholders. |
Download this position's data
Fundamentals, scenario matrix, and risk/reward table — exported exactly as published on this page, no reformatting.